RU2015132315A - Способ регулирования полового поведения самцов млекопитающих - Google Patents
Способ регулирования полового поведения самцов млекопитающих Download PDFInfo
- Publication number
- RU2015132315A RU2015132315A RU2015132315A RU2015132315A RU2015132315A RU 2015132315 A RU2015132315 A RU 2015132315A RU 2015132315 A RU2015132315 A RU 2015132315A RU 2015132315 A RU2015132315 A RU 2015132315A RU 2015132315 A RU2015132315 A RU 2015132315A
- Authority
- RU
- Russia
- Prior art keywords
- tropic
- hypothalamus
- therapeutic
- nuclei
- regulating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (6)
1. Способ регулирования полового поведения самцов животных, включающий введение мелатонина и гестагена, отличающийся тем, что дополнительно вводят тропный к задним ядрам гипоталамуса α-адреноблокатор, при этом совокупность указанных биологически активных веществ вводят в терапевтических дозах в любой период полового цикла.
2. Способ по п. 1, отличающийся тем, что в качестве α-адреноблокатора, тропного к задним ядрам гипоталамуса, используют пророксан и(или) бутироксан.
3. Фармацевтическая композиция для регулирования полового поведения самцов животных, предназначенная для трансдермального введения «Спот-он», имеющая pH в интервале от 4,0 до 6,0 и содержащая терапевтические количества мелатонина, гестагена и α-адреноблокатора, тропного к задним ядрам гипоталамуса, при следующем соотношении компонентов, масс.%:
4. Фармацевтическая композиция по п. 3, отличающаяся тем, что в качестве гестагена используют 6-хлор-1β,2β-дигидро-17-гидрокси-3'H-циклопропа[1,2]прегна-1,4,6-триен-3,20-дионацетат (ципротерона ацетат) или (и) 17α-цианометил-17β-гидроксиэстра-4,9-диен-3-он (диеногест), или (и) (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-гексадекагидро-10,13-диметилспиро-[17H-дициклопропа-[6,7:15,16]циклопента[а]фенантрен-17,2'(5'H)-фуран]-3,5'(2H)дион (дроспиренон).
5. Фармацевтическая композиция по п. 3, отличающаяся тем, что в качестве α-адреноблокатора, тропного к задним ядрам гипоталамуса, используют пророксан или (и) бутироксан.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015132315A RU2616252C2 (ru) | 2015-08-04 | 2015-08-04 | Способ регулирования полового поведения самцов млекопитающих |
EA201890438A EA035143B1 (ru) | 2015-08-04 | 2016-08-01 | Способ регулирования полового поведения самцов млекопитающих |
EP16844787.8A EP3332778A4 (en) | 2015-08-04 | 2016-08-01 | METHOD FOR CONTROLLING SEXUAL BEHAVIOR IN MALE MAMMALS |
PCT/RU2016/000498 WO2017044003A1 (ru) | 2015-08-04 | 2016-08-01 | Способ регулирования полового поведения самцов млекопитающих |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015132315A RU2616252C2 (ru) | 2015-08-04 | 2015-08-04 | Способ регулирования полового поведения самцов млекопитающих |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2015132315A true RU2015132315A (ru) | 2017-02-07 |
RU2616252C2 RU2616252C2 (ru) | 2017-04-13 |
Family
ID=58240274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015132315A RU2616252C2 (ru) | 2015-08-04 | 2015-08-04 | Способ регулирования полового поведения самцов млекопитающих |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3332778A4 (ru) |
EA (1) | EA035143B1 (ru) |
RU (1) | RU2616252C2 (ru) |
WO (1) | WO2017044003A1 (ru) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU601736B2 (en) * | 1986-05-23 | 1990-09-20 | Sanofi Sante Nutrition Animale Sa | Coated veterinary implants |
RU2067001C1 (ru) * | 1987-03-23 | 1996-09-27 | Эпплайд Медикал Рисерч, Лтд. | Способ снижения риска заболевания раком молочной железы |
US4855305A (en) * | 1987-03-23 | 1989-08-08 | Applied Medical Research | Compositions and methods of effecting contraception utilizing melatonin |
IN171596B (ru) * | 1989-06-27 | 1992-11-21 | Cohen Michael | |
RU2163809C2 (ru) * | 1999-03-17 | 2001-03-10 | Общество с ограниченной ответственностью "Группа ЭКСПА" | Средство для регулирования половой активности у кошек и собак |
AU2003206433A1 (en) * | 2002-02-15 | 2003-09-04 | Pantarhei Bioscience B.V. | A pulmonary drug delivery composition containing a progestogen and an androgen for use in a contraceptive method in males |
RU2233586C1 (ru) * | 2002-12-15 | 2004-08-10 | Зейналов Орхан Ахмед-оглы | Средство для регуляции репродуктивной функции и половой активности позвоночных животных и способ регуляции репродуктивной функции и половой активности позвоночных животных |
-
2015
- 2015-08-04 RU RU2015132315A patent/RU2616252C2/ru active
-
2016
- 2016-08-01 EA EA201890438A patent/EA035143B1/ru unknown
- 2016-08-01 EP EP16844787.8A patent/EP3332778A4/en not_active Withdrawn
- 2016-08-01 WO PCT/RU2016/000498 patent/WO2017044003A1/ru active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EA201890438A1 (ru) | 2018-09-28 |
EP3332778A1 (en) | 2018-06-13 |
EP3332778A4 (en) | 2019-04-17 |
RU2616252C2 (ru) | 2017-04-13 |
EA035143B1 (ru) | 2020-05-06 |
WO2017044003A1 (ru) | 2017-03-16 |
EA201890438A8 (ru) | 2018-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102181168B1 (ko) | Hbv 캡시드 조립 억제제와 인터페론의 조합 치료 | |
US20040138109A1 (en) | Potent inhibitor of HCV serine protease | |
MX2020003381A (es) | Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. | |
JP2018524298A5 (ru) | ||
JP2013521279A (ja) | Hcv複製の阻害剤としての医薬併用剤 | |
Gane et al. | Phase 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV core inhibitor: LB-19 | |
KR20180129943A (ko) | 캡시드 조립 억제제를 포함하는 배합물 및 방법 | |
NZ591205A (en) | Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same | |
JP2006502969A (ja) | 内因性性腺刺激ホルモン産生の増強 | |
JP2013522229A5 (ru) | ||
RU2017134443A (ru) | Способ лечения с применением традипитанта | |
JP2018090566A5 (ru) | ||
JP2014509658A (ja) | ガン処置方法 | |
MY150682A (en) | Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival | |
WO2012041771A1 (en) | Combination therapy for treating hcv infection | |
JP2015519368A5 (ru) | ||
JP2019519525A (ja) | Phy906抽出物、スクテラリア・バイカレンシス・ジョージ(s)抽出物、またはそのような抽出物に由来する化合物を含む併用療法を用いることによる、抗免疫チェックポイント阻害剤の治療指数の改善方法 | |
RU2017127509A (ru) | Композиции и способы для улучшенного мышечного метаболизма | |
RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
RU2015132315A (ru) | Способ регулирования полового поведения самцов млекопитающих | |
RU2018127752A (ru) | Способы применения ингибиторов каспаз при лечении заболеваний печени | |
RU2016136666A (ru) | Составы на основе прогестерона | |
WO2015095572A1 (en) | Methods for treating liver transplant recipients | |
WO2022213870A1 (zh) | 通过口服给药抑制CD4+Treg细胞的药物和方法 | |
MX2021011614A (es) | Formas solidas de un compuesto del modificador alosterico de la proteina del nucleo del vhb. |